Frequent gout flares

In this prospective cohort study of 444 gout patients followed for a median of 5.66 years, 108 patients (24.3%) developed type 2 diabetes mellitus. Multivariate logistic regression demonstrated that experiencing ≥4 arthritis attacks per year was the strongest independent risk factor for T2DM development, with an odds ratio of 5.23 (95% CI: 2.98–9.19; p=0.0001). This five-fold increased risk remained significant after adjusting for other variables including BMI, age, physical activity, diet, and medication use.

View Source →

In this prospective cohort of 444 gout patients followed 2-8 years, having more than 4 gout attacks per year was significantly associated with type 2 diabetes development. Among patients who developed diabetes, 67.6% had frequent attacks compared to only 31.6% of those who remained diabetes-free (p=0.001). Logistic regression confirmed that >4 gout exacerbations per year independently increased diabetes risk, indicating microcrystalline inflammation contributes to metabolic dysfunction.

View Source →

In the prospective cohort of 444 gout patients, those who developed type 2 diabetes had significantly more frequent arthritis attacks. Among patients who developed diabetes, 67.6% experienced more than 4 gout attacks per year compared to only 31.6% of those who did not develop diabetes (p=0.001). Logistic regression confirmed that more than 4 exacerbations of gout per year independently increased the risk of developing type 2 diabetes.

View Source →

In this prospective cohort study of gout patients followed for 6 months, serum CA72-4 levels were markedly elevated in gouty arthritis patients with median 4.55 U/ml (IQR 1.56-32.64) compared to hyperuricemia patients at 1.47 U/ml (IQR 0.87-3.29), healthy controls at 1.59 U/ml (IQR 0.99-3.39), and other arthritis types including RA at 1.58 U/ml, OA at 1.54 U/ml, SpA at 1.56 U/ml, and septic arthritis at 1.38 U/ml. Elevated CA72-4 above 6.9 U/ml was the strongest predictor of gout flares with hazard ratio of 3.889. Prophylactic colchicine showed significant effectiveness specifically in patients with high CA72-4 levels (P = 0.014).

View Source →

This prospective cohort study followed 1,164 gout patients over 36 months across 20 general practices. Six distinct flare trajectories were identified: 'frequent and persistent' (n=95, 8%), 'gradually worsening' (n=276, 24%), 'frequent then improving' (n=14, 1%), 'moderately frequent' (n=287, 25%), 'moderately frequent then improving' (n=143, 12%), and 'infrequent' (n=349, 30%). The 'frequent and persistent,' 'gradually worsening,' and 'frequent then improving' classes had the highest proportions of members with estimated glomerular filtration rate <60 ml/minute/1.73 m². Patients with infrequent flares showed lower serum urate levels, suggesting those with frequent flares may benefit from medical reassessment.

View Source →

Among 1,164 gout patients followed for 36 months, the 'gradually worsening' trajectory class (n=276) and 'frequent and persistent' class (n=95) together represented approximately 32% of participants. Both classes had the highest proportions of members with estimated glomerular filtration rate <60 ml/minute/1.73 m² and socioeconomic deprivation. The 'infrequent' flare class (n=349, 30% of cohort) was associated with lower serum urate levels, suggesting that patients with frequent flares may benefit from medical evaluation and treatment optimization.

View Source →

The 2020 ACR Guideline strongly recommends initiating urate-lowering therapy for patients with frequent gout flares, defined as 2 or more flares annually. This strong recommendation was among 16 issued by the voting panel using GRADE methodology. The systematic review identified gout flare frequency as a critical outcome, with the treat-to-target strategy aiming for serum urate below 6 mg/dL to reduce flare occurrence and prevent joint damage.

View Source →

Among 983 gout patients analyzed, the number of flares in the year previous to the renal event was independently associated with higher risk of acute kidney injury in multivariable Cox survival analysis. Of the cohort, 55 patients (5.6%) developed AKI classified by RIFLE criteria (risk, injury, failure). Polyarticular joint distribution was also significantly associated with increased renal events. These findings indicate that recurrent flare frequency serves as a clinical marker for elevated AKI susceptibility.

View Source →